JP2019504104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504104A5 JP2019504104A5 JP2018540806A JP2018540806A JP2019504104A5 JP 2019504104 A5 JP2019504104 A5 JP 2019504104A5 JP 2018540806 A JP2018540806 A JP 2018540806A JP 2018540806 A JP2018540806 A JP 2018540806A JP 2019504104 A5 JP2019504104 A5 JP 2019504104A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- substituted
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 19
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 description 30
- 125000001072 heteroaryl group Chemical group 0.000 description 13
- 125000000547 substituted alkyl group Chemical group 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 6
- -1 substituted Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 102200158794 rs34532478 Human genes 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291298P | 2016-02-04 | 2016-02-04 | |
| US62/291,298 | 2016-02-04 | ||
| PCT/IB2017/050568 WO2017134596A1 (en) | 2016-02-04 | 2017-02-02 | C-3 and c-17 modified triterpenoids as hiv-1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504104A JP2019504104A (ja) | 2019-02-14 |
| JP2019504104A5 true JP2019504104A5 (enExample) | 2020-01-30 |
| JP6735837B2 JP6735837B2 (ja) | 2020-08-05 |
Family
ID=57995251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540806A Active JP6735837B2 (ja) | 2016-02-04 | 2017-02-02 | Ｈｉｖ−１阻害剤としてのｃ−３およびｃ−１７修飾トリテルペノイド |
Country Status (39)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| US20210347813A1 (en) | 2018-04-24 | 2021-11-11 | Viiv Healthcare Uk (No. 5) Limited | Compounds with hiv maturation inhibitory activity |
| CA3164528A1 (en) | 2019-12-09 | 2021-06-17 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
| WO2025068743A1 (en) | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| WO2025037232A1 (en) | 2023-08-11 | 2025-02-20 | ViiV Healthcare UK (No.4) Limited | Tosylate salt form of a maturation inhibitor for treatment of hiv |
| CN121909019A (zh) | 2023-09-27 | 2026-04-21 | Viiv保健英国第三有限公司 | 药物组合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| GB0301227D0 (en) | 2003-01-20 | 2003-02-19 | Keen Group Ltd | Seating apparatus |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| MXPA06010592A (es) | 2004-03-17 | 2007-06-12 | Panacos Pharmaceuticals Inc | Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico. |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| AU2009214779A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17beta lupane derivatives |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| FR2956034B1 (fr) | 2010-02-09 | 2012-02-10 | Thales Sa | Dispositif d'entrainement pour des joueurs de rugby |
| BR112012030818A2 (pt) | 2010-06-04 | 2019-09-24 | Bristol-Myers Squibb Company | "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" |
| WO2011153319A1 (en) | 2010-06-04 | 2011-12-08 | Bristol-Myers Squibb Company | C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| DE102010017786A1 (de) | 2010-07-07 | 2012-01-12 | Continental Reifen Deutschland Gmbh | Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung |
| HRP20151212T1 (hr) | 2011-01-31 | 2015-12-04 | Bristol-Myers Squibb Company | C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P |
| JP6001560B2 (ja) * | 2011-01-31 | 2016-10-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド |
| EP2791102B1 (en) * | 2011-12-14 | 2016-05-18 | Glaxosmithkline LLC | Propenoate derivatives of betulin |
| US8906889B2 (en) * | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) * | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9378035B2 (en) | 2012-12-28 | 2016-06-28 | Commvault Systems, Inc. | Systems and methods for repurposing virtual machines |
| EA027371B1 (ru) * | 2013-02-06 | 2017-07-31 | Бристол-Майерс Сквибб Компани | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич |
| JP6186012B2 (ja) | 2013-02-25 | 2017-08-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ−３アルキルおよびアルケニル修飾ベツリン酸誘導体 |
| CN104877015B (zh) * | 2014-02-28 | 2019-02-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种三萜-多肽缀合物、其药物组合物及用途 |
| NZ724644A (en) | 2014-04-11 | 2023-07-28 | Viiv Healthcare Uk No 4 Ltd | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP4438041A3 (en) | 2016-02-04 | 2025-01-01 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
-
2017
- 2017-02-01 AR ARP170100255A patent/AR107512A1/es active IP Right Grant
- 2017-02-02 HU HUE17704093A patent/HUE054337T2/hu unknown
- 2017-02-02 KR KR1020187025343A patent/KR102795662B1/ko active Active
- 2017-02-02 RS RS20210450A patent/RS61746B1/sr unknown
- 2017-02-02 AU AU2017215529A patent/AU2017215529B2/en active Active
- 2017-02-02 EA EA201891649A patent/EA036211B1/ru unknown
- 2017-02-02 BR BR112018015629-9A patent/BR112018015629B1/pt active IP Right Grant
- 2017-02-02 US US16/071,925 patent/US10421774B2/en active Active
- 2017-02-02 SI SI201730647T patent/SI3411381T1/sl unknown
- 2017-02-02 MY MYPI2018702694A patent/MY199668A/en unknown
- 2017-02-02 DK DK17704093.8T patent/DK3411381T3/da active
- 2017-02-02 RU RU2018130181A patent/RU2716502C2/ru active
- 2017-02-02 JO JOP/2017/0029A patent/JOP20170029B1/ar active
- 2017-02-02 LT LTEP17704093.8T patent/LT3411381T/lt unknown
- 2017-02-02 MA MA43960A patent/MA43960B1/fr unknown
- 2017-02-02 TW TW106103410A patent/TWI719126B/zh active
- 2017-02-02 WO PCT/IB2017/050568 patent/WO2017134596A1/en not_active Ceased
- 2017-02-02 SM SM20210210T patent/SMT202100210T1/it unknown
- 2017-02-02 PE PE2018001378A patent/PE20181355A1/es unknown
- 2017-02-02 MA MA053358A patent/MA53358A/fr unknown
- 2017-02-02 UY UY0001037109A patent/UY37109A/es not_active Application Discontinuation
- 2017-02-02 ES ES17704093T patent/ES2862325T3/es active Active
- 2017-02-02 SG SG11201806388XA patent/SG11201806388XA/en unknown
- 2017-02-02 ES ES21152161T patent/ES2957767T3/es active Active
- 2017-02-02 PT PT177040938T patent/PT3411381T/pt unknown
- 2017-02-02 CN CN201780018790.8A patent/CN109153700B/zh active Active
- 2017-02-02 EP EP17704093.8A patent/EP3411381B1/en active Active
- 2017-02-02 JP JP2018540806A patent/JP6735837B2/ja active Active
- 2017-02-02 PL PL17704093T patent/PL3411381T3/pl unknown
- 2017-02-02 MX MX2018009514A patent/MX375118B/es active IP Right Grant
- 2017-02-02 EP EP21152161.2A patent/EP3831839B1/en active Active
- 2017-02-02 MD MDE20181181T patent/MD3411381T2/ro unknown
- 2017-02-02 UA UAA201808249A patent/UA123867C2/uk unknown
- 2017-02-02 CA CA3013417A patent/CA3013417C/en active Active
- 2017-02-02 HR HRP20210502TT patent/HRP20210502T1/hr unknown
- 2017-02-02 CR CR20180387A patent/CR20180387A/es unknown
-
2018
- 2018-07-23 IL IL260741A patent/IL260741B/en active IP Right Grant
- 2018-07-26 ZA ZA2018/05044A patent/ZA201805044B/en unknown
- 2018-07-30 DO DO2018000174A patent/DOP2018000174A/es unknown
- 2018-07-31 CO CONC2018/0008157A patent/CO2018008157A2/es unknown
- 2018-08-02 CL CL2018002084A patent/CL2018002084A1/es unknown
-
2019
- 2019-08-07 US US16/534,208 patent/US11084845B2/en active Active
-
2021
- 2021-04-08 CY CY20211100303T patent/CY1124353T1/el unknown
- 2021-06-09 US US17/342,941 patent/US20210323997A1/en not_active Abandoned
-
2022
- 2022-12-16 US US18/083,037 patent/US20230295220A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503595A5 (enExample) | ||
| JP2014507422A5 (enExample) | ||
| RU2018130181A (ru) | C-3 и C-17 модифицированные тритерпеноиды в качестве ингибиторов ВИЧ-1 | |
| JP2016507558A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| PH12021551116A1 (en) | Functionalized heterocycles as antiviral agents | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| JP2024543976A5 (enExample) | ||
| JP2022068329A5 (enExample) | ||
| JP2018510139A5 (enExample) | ||
| JP2017504642A5 (enExample) | ||
| JP2016518434A5 (enExample) | ||
| JP2012522003A5 (enExample) | ||
| JP2020500178A5 (enExample) | ||
| JP2017536395A5 (enExample) | ||
| JP2024516371A5 (enExample) | ||
| JP2020505423A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| JP2004515493A5 (enExample) | ||
| MX2021003253A (es) | Heterociclos funcionalizados como agentes antivirales. | |
| JP2002524503A5 (enExample) | ||
| JP2019528279A5 (enExample) | ||
| JP2017531673A5 (enExample) | ||
| RU97113367A (ru) | Производные нейраминовой кислоты, их получение и применение в медицине | |
| JP2015508068A5 (enExample) |